Recombinant human granulocyte colony-stimulating factor (rh-G-CSF) may accelerate hematopoietic recovery after HLA-identical sibling allogeneic peripheral blood stem cell transplantation
| Autor: | C. Üstün, Onder Arslan, Meral Beksac, Taner Demirer, Hamdi Akan, E Akçağlayan, Osman Ilhan, Nahide Konuk, Akin Uysal, Mutlu Arat, Muhit Ozcan, Gunhan Gurman, Harika Çelebi, Haluk Koç |
|---|---|
| Rok vydání: | 2001 |
| Předmět: |
Adult
Male medicine.medical_specialty Adolescent Platelet Engraftment Graft vs Host Disease Infections Gastroenterology Nuclear Family Recurrence Internal medicine Granulocyte Colony-Stimulating Factor medicine Mucositis Humans Transplantation Homologous Survival rate Transplantation business.industry Hematopoietic Stem Cell Transplantation Hematology Middle Aged medicine.disease Recombinant Proteins Hematopoiesis Granulocyte colony-stimulating factor Histocompatibility Surgery Survival Rate Leukemia Treatment Outcome Case-Control Studies Hematologic Neoplasms Absolute neutrophil count Female business |
| Zdroj: | Bone Marrow Transplantation. 27:499-505 |
| ISSN: | 1476-5365 0268-3369 |
| DOI: | 10.1038/sj.bmt.1702816 |
| Popis: | We studied the effects of recombinant human granulocyte colony-stimulating factor (G-CSF) on hematopoietic recovery and clinical outcome in patients undergoing allogeneic peripheral blood stem cell (PBSC) transplantation. Fifty-six patients with hematological malignancies who underwent allogeneic PBSC transplantation between 1995 and 1998 were entered into this study. Twenty-eight patients who received daily G-CSF from day +1 after allogeneic PBSC transplantation until the absolute neutrophil count (ANC) reached >0.5 x 10(9)/l for 3 consecutive days were compared with 28 patients (control group) who did not receive G-CSF in a non-randomized manner. The study group and the control group were comparable with respect to baseline patient and transplantation characteristics. Median times to ANC of >0.5 x 10(9)/l and 1 x 10(9)/l with or without G-CSF were 12 days (range 8-21), 13 days (10-32) (P = 0.04) and 13 days (9-21), 15 days (11-44) (P = 0.02), respectively. Median times to reach a platelet count of >20 x 10(9)/l with and without G-CSF were 11 days (0-20) and 13 days (9-26), respectively (P = 0.03). The incidence of febrile episodes was significantly lower with G-CSF, 75% vs 100% (P = 0.008). Patients receiving G-CSF had less grade III-IV mucositis than those who did not receive G-CSF (P = 0.01). There was also no increase in the incidence and severity of acute GVHD in patients using G-CSF (P = 0.22). Although the number of relapsing patients was greater in the G-CSF group (seven vs three patients), this was not statistically significant (P = 0.24). Disease-free and overall survival rates did not differ between the two groups (P = 0.58 and 0.53, respectively). The administration of G-CSF after allogeneic PBSC transplantation provided faster neutrophil and platelet engraftment associated with less severe mucositis and less febrile episodes. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|